Coaxial MICS with toric IOL is a safe and effective treatment for cataract patients

Article

Implantation of a toric IOL after microincision cataract surgery (MICS) is a safe and successful way to correct astigmatism in cataract patients.

Implantation of a toric IOL after microincision cataract surgery (MICS) is a safe and successful way to correct astigmatism in cataract patients, stated a study published in the Journal of Cataract and Refractive Surgery.

Professor Jorge L. Alió et al., Vissum-Instituto Oftalmológico de Alicante, Spain, conducted a prospective, nonrandomized study on 21 eyes of 12 patients who had moderate to high astigmatism and cataracts. MICS was performed on all patients, followed by the implantation of an Acri.Comfort 646 TLC toric IOL in the capsular bag.

The outcome measures were uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), residual refractive sphere, residual refractive and keratometric cylinders and IOL axis alignment. All were measured 3 months postoperatively and the Alpins method was used to measure vector analysis of astigmatism.

It was found that the UDVA was 20/40 or better in 16 eyes and CDVA was 20/30 or better in 18 eyes. The mean refractive cylinder reduced postoperatively from -4.46 D ± 2.23 D to -0.45 D to 0.63 D. The mean index of success was 0.11 ± 0.15, with 91% of astigmatism corrected. Mean IOL axis rotation was -1.75˚ ± 2.93˚and the rotation was 10˚ or lower in all eyes.

The combination of MICS and toric IOL implantation posed no risks or complications. It was considered as a safe and accurate way of eradicating moderate to high astigmatism in cataract patients.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.